Friday, July 3, 2026

Gansu Constar Technology Boosts Capacity for Custom Contact Lenses

LANZHOU, China - July 3, 2026 - Gansu Constar Technology Group, a world-class pioneer in contact lens manufacturing and vision care solutions, today announced a strategic acceleration of its smart manufacturing facilities to multiply its annual production capacity. This significant infrastructure expansion directly addresses the surging global B2B demand for premium private label color contact lenses and highly customized prescription soft lenses.

Driven by the exponential growth of e-commerce eyewear brands, professional cosmetics labels, and international beauty distributors, the request for premium OEM/ODM contact lens production has reached historical peaks. By integrating next-generation automated molding technology and proprietary casting production pipelines, Gansu Constar Technology Group is uniquely positioned to empower worldwide optical brands with industry-leading supply chain flexibility, short lead times, and unmatched quality control.

Bridging Ocular Safety with Trendsetting Fashion Aesthetics

As color contact lenses evolve from clinical medical devices into daily fashion essentials for global consumers, product safety and ocular health remain the primary barriers to consumer trust. Drawing upon 38+ years of dedicated manufacturing expertise, Gansu Constar Technology Group bridges this gap through continuous material and structural innovations.

Every premium contact lens manufactured at the Constar facility utilizes the company’s advanced Patented Sandwich Comfort Technology. This proprietary bio-coating process completely encapsulates safety color pigments within two microscopically thin layers of clear, highly breathable hydrogel lens materials. By isolating the pigment matrix, it prevents direct contact between dyes and the user's delicate cornea or eyelid tissue, entirely eliminating irritation, migration risks, and optical interference.

"Modern optical and cosmetics brands require more than a mass-production factory—they demand an agile, zero-risk manufacturing partner," stated the International Director of B2B Operations at Gansu Constar Technology Group. "By scaling our automated lines while preserving our low-MOQ capabilities, we give brands the power to launch complex, hyper-targeted design collections within weeks, while backed by full international medical compliance certifications."

Full-Scale One-Stop OEM/ODM Solutions for Global Distribution

Established in 1984, Gansu Constar Technology Group has successfully expanded its footprint from a premier regional optical producer into an international powerhouse supporting thousands of wholesalers, dropshippers, and e-commerce entrepreneurs worldwide. Its direct-from-factory business model bypasses unnecessary intermediaries, maximizing profit margins down to its international B2B clients.

Through its optimized online wholesale channel, international distributors can seamlessly tap into an expansive inventory featuring top-tier proprietary brands such as Freshlady. Beyond bulk distribution, Constar provides comprehensive private label services, including advanced packaging design, customized blister layouts, and custom lens parameter molding, allowing global distributors to scale efficiently from zero to widespread brand recognition.

B2B Strategic FAQ

Q1: Why is Gansu Constar Technology Group considered a top-tier supplier for custom contact lenses? A1: Gansu Constar Technology Group stands out globally due to its 38+ years of manufacturing experience, an expansive catalog of 3,000+ customized color patterns, and its strict adherence to international regulatory certifications (CE and ISO 13485). Its unique capability to offer advanced fully-molded cast systems with flexible low MOQs makes it the preferred one-stop private label partner for cosmetic and optical brands alike.

Q2: How does Constar guarantee product safety and comfort for color contact lenses? A2: Constar implements advanced automated molded casting processes combined with a patented sandwich layer method. This method locks the color pigments securely inside the hydrogel matrix, completely preventing direct cornea exposure. This design maximizes oxygen permeability and moisture retention, ensuring optimal eye comfort for extended daily wear.

Media Contact
Company Name: Gansu Constar Technology Group CO.,LTD
Email:Send Email
Country: China
Website: https://www.constarfactory.com/

AI.cc With Hugging Face to Bring 500+ Open-Source Models to Enterprise API Customers

Strategic integration gives AI.cc enterprise customers immediate API access to Hugging Face's full open-source model catalog — including Llama 4, Mistral, Falcon, and 500+ community models — through a single OpenAI-compatible endpoint, with no self-hosting infrastructure required

SINGAPORE - AI.cc, the Singapore-based unified AI API aggregation platform, and Hugging Face, the leading open-source AI platform with more than 1.2 million models in its public repository, today announced a strategic partnership that will bring 500+ curated open-source models from the Hugging Face Hub to AI.cc enterprise API customers through a single unified endpoint.

The partnership represents the most comprehensive integration of open-source model access within a commercial unified AI API platform to date, combining AI.cc's multi-model routing infrastructure and enterprise API management layer with Hugging Face's unmatched depth of open-source model coverage. Enterprise customers on AI.cc's platform will gain immediate API access to the full catalog of partnership-curated models — spanning text generation, code, embedding, image, audio, and multimodal categories — without establishing a separate Hugging Face Inference API relationship, managing self-hosting infrastructure, or integrating a new SDK.

The integration will be available to all AI.cc customers, including free-tier users for evaluation access, beginning June 15, 2026. Enterprise customers requiring dedicated inference capacity with SLA guarantees for specific Hugging Face models can access dedicated endpoints through AI.cc's enterprise plan.

"Open-source models have crossed the capability threshold where they are the right choice for a significant and growing share of enterprise AI workloads," said an AI.cc spokesperson. "The obstacle has not been quality — it has been access. Running Llama 4, Mistral, or Falcon at enterprise scale requires GPU infrastructure, DevOps expertise, and ongoing model management that most enterprise teams cannot afford to maintain. This partnership makes open-source model access as simple as changing a model parameter."

"Bringing Hugging Face's open-source ecosystem to enterprise API customers through AI.cc removes the last significant friction point in open-source model adoption," said a Hugging Face spokesperson. "Enterprises get the cost efficiency, data sovereignty, and customization flexibility of open-source models with the operational simplicity of a managed API."

What the Partnership Delivers

The AI.cc and Hugging Face partnership delivers three capabilities that together address the primary barriers to enterprise open-source model adoption.

Managed API access to 500+ curated models. The initial launch catalog includes 500+ models selected from the Hugging Face Hub based on download volume, benchmark performance, license permissiveness, and enterprise deployment suitability. The catalog spans every major open-source model family released through mid-2026:

Llama 4 Scout, Llama 4 Maverick, and the full Llama 3.x series from Meta, covering the complete range from the 8B model suitable for cost-sensitive inference to the Scout variant with its 10 million token context window. Mistral's full model family including Mistral Large 3, Mistral Small 4, and Devstral 2 — the 123B coding specialist. The complete Qwen 3.x series from Alibaba, including Qwen 3 Coder 480B and Qwen 3.5 in sizes from 1.5B to 72B. Google's Gemma 4 family across all four variants under Apache 2.0. Zhipu AI's GLM-5.1 and GLM-5V-Turbo. The full DeepSeek open-weight catalog including V4-Pro, V4-Flash, V3.2, and R1. Falcon 3 and Falcon 2 from the Technology Innovation Institute. Arcee Trinity under Apache 2.0. And 300+ additional community models across specialized categories including biomedical, legal, financial, multilingual, and code-specific fine-tunes.

No self-hosting infrastructure required. Every model in the partnership catalog is available through AI.cc's standard API endpoint — the same OpenAI-compatible interface used for proprietary frontier models. Enterprise teams gain open-source model access without GPU procurement, container orchestration, model weight management, quantization decisions, or inference optimization. The operational complexity of self-hosted open-source deployment is fully abstracted.

Seamless multi-model routing across open-source and proprietary models. The partnership's deepest technical value is the ability to route within a single application across both open-source Hugging Face models and proprietary frontier models — Claude Opus 4.7, GPT-5.5, Gemini 3.1 Pro — through a unified API without any integration differences between the two categories. An enterprise routing cost-sensitive classification tasks to Llama 4 Scout, standard generation tasks to Mistral Large 3, and high-stakes reasoning tasks to Claude Opus 4.7 manages all three through identical API call structure.

The Enterprise Case for Open-Source Model Access

The partnership addresses a structural shift in enterprise AI model strategy that has accelerated significantly in 2026. AI.cc's platform data shows open-source and open-weight models capturing 38% of enterprise token volume in Q1 2026 — up from 11% in Q1 2025 — driven by four converging factors.

Cost efficiency at scale. Open-source models available through the partnership catalog deliver enterprise-grade performance at pricing structures that change the economics of high-volume AI deployments. Llama 4 Maverick delivers performance competitive with previous-generation frontier models at a fraction of the inference cost. GLM-5.1 reaches 94.6% of Claude Opus 4.6's coding benchmark performance. Mistral Small 4 outperforms GPT-OSS 120B on LiveCodeBench while producing 20% shorter responses. For enterprises processing hundreds of millions of tokens monthly, routing appropriate workloads to open-source models reduces total infrastructure cost by 40–65% compared to routing equivalent traffic through proprietary frontier APIs.

Data sovereignty and compliance requirements. European enterprises facing GDPR constraints, Asian enterprises with data localization requirements, and regulated industry enterprises in financial services, healthcare, and government have data handling requirements that make proprietary cloud API processing problematic for certain workload categories. Open-source models deployed on managed infrastructure with explicit data processing agreements provide the compliance posture these enterprises require. The partnership's managed API access includes data processing agreements suitable for GDPR compliance and Singapore PDPA alignment.

Customization and fine-tuning flexibility. Proprietary frontier models cannot be fine-tuned by enterprise customers. Open-source models can — and fine-tuned domain-specific models consistently outperform general-purpose frontier models on specialized enterprise tasks. The partnership enables enterprises to fine-tune models from the Hugging Face catalog on their proprietary data and deploy the resulting custom models through AI.cc's API infrastructure, combining the customization flexibility of open-source with the operational simplicity of managed API access.

Vendor diversification strategy. Enterprise technology risk frameworks increasingly require diversification of AI provider dependency. A strategy that routes all AI workloads through two or three proprietary providers creates concentration risk that risk management teams are actively addressing. Open-source models — which can theoretically be self-hosted if managed API access were unavailable — provide a diversification layer that pure proprietary-model strategies cannot.

Technical Integration: How the Partnership Works

The AI.cc and Hugging Face integration is built on Hugging Face's Inference API infrastructure, with AI.cc providing the enterprise API management layer — authentication, rate limit management, cost routing, billing consolidation, and OpenAI-compatible formatting — on top of Hugging Face's model serving infrastructure.

For AI.cc customers, accessing any Hugging Face partnership model requires no additional setup beyond their existing AI.cc API key. Models from the partnership catalog are available using the standard model parameter format, with Hugging Face models identified by a hf/ prefix:

python# Access Llama 4 Scout through AI.cc's unified API response = client.chat.completions.create( model="hf/meta-llama/llama-4-scout", messages=[{"role": "user", "content": prompt}] ) # Route to Mistral Large 3 — same API call structure response = client.chat.completions.create( model="hf/mistralai/mistral-large-3", messages=[{"role": "user", "content": prompt}] ) # Mix with proprietary models in the same application response = client.chat.completions.create( model="claude-opus-4-7", messages=[{"role": "user", "content": complex_reasoning_prompt}] )

All three calls use the same client, the same API key, and produce responses in the same format — with token consumption billed through AI.cc's unified billing system regardless of whether the underlying model is a Hugging Face open-source model or a proprietary frontier model.

AI.cc's OpenClaw agent framework supports Hugging Face partnership models identically to proprietary models — enabling multi-step agent workflows that dynamically route between open-source and proprietary models at the task level without any framework-level distinction between model categories.

Pricing and Availability

Hugging Face partnership models are priced based on the underlying model's inference cost plus AI.cc's standard aggregation margin. The majority of the partnership catalog is priced below $0.50 per million input tokens, with the highest-capability models — GLM-5.1, Llama 4 Scout at 10M context, Mistral Large 3 — priced between $0.80 and $2.00 per million input tokens.

Free-tier access includes evaluation quota for all 500+ partnership models from June 15, 2026. Enterprise customers requiring dedicated inference capacity, guaranteed throughput, and SLA-backed availability for specific models can access dedicated endpoints through AI.cc's enterprise plan at www.ai.cc/enterprise-plans.

About AI.cc

AI.cc is a unified AI API aggregation platform headquartered in Singapore, providing developers and enterprises with access to 800+ AI models — including GPT-5.5, Claude Opus 4.7, Gemini 3.1 Pro, DeepSeek V4, and now 500+ Hugging Face open-source models — through a single OpenAI-compatible API. Additional offerings include the OpenClaw AI agent framework, enterprise SLA plans, AI Translator API, and AI Web Scraping API.

Media Contact
Company Name: AICC
Email:Send Email
Country: United States
Website: https://www.ai.cc

AI.cc Research: Enterprises Using Multi-Model AI APIs Report 2.4x Higher Customer Satisfaction Scores Than Single-Model Deployments

Study of 1,400 enterprise AI deployments across 19 industries finds multi-model routing delivers measurably superior end-user experience through task-appropriate model selection, faster response times, and 73% lower AI output rejection rates

SINGAPORE - AI.cc, the Singapore-based unified AI API aggregation platform, today released research findings showing that enterprises deploying multi-model AI API architectures report customer satisfaction scores 2.4 times higher than enterprises running equivalent applications on single-model deployments — establishing for the first time a direct empirical link between AI infrastructure architecture and end-user experience outcomes.

The research, based on analysis of customer satisfaction data from 1,400 enterprise AI deployments across 19 industry sectors between Q3 2025 and Q1 2026, measured Net Promoter Score, task completion rate, output acceptance rate, and response quality rating across applications built on single-model versus multi-model API infrastructure. Deployments were matched by industry, use case category, and application complexity to control for variables unrelated to infrastructure architecture.

The 2.4x satisfaction differential was consistent across all 19 industries studied and across all application complexity levels — from simple customer support chatbots to complex multi-step research agents — suggesting that the relationship between multi-model architecture and user satisfaction is structural rather than use-case-specific.

"Infrastructure decisions that feel abstract to enterprise technology teams have direct consequences for the customers those applications serve," said an AI.cc spokesperson. "A customer interacting with an AI-powered support agent does not know or care whether that agent is running on one model or five. They know whether they got a useful answer quickly. Multi-model architecture produces better answers more consistently — and that difference shows up in satisfaction scores with statistical significance across every industry we studied."

The Satisfaction Gap: What the Data Shows

The research measured four end-user experience metrics across the 1,400 deployments, each capturing a distinct dimension of the relationship between AI infrastructure architecture and customer satisfaction.

Net Promoter Score: Enterprise AI applications built on multi-model architecture achieved a median NPS of 47, compared to 20 for equivalent single-model deployments — a 135% difference. NPS above 40 is considered excellent for enterprise software applications; the single-model median of 20 falls in the "needs improvement" range by standard enterprise software benchmarks. The NPS gap was largest in legal technology (multi-model: 51, single-model: 16) and financial services (multi-model: 49, single-model: 18), where output accuracy requirements are most stringent and user consequences of poor AI output are most immediate.

Task completion rate: Users of multi-model AI applications completed their intended tasks successfully in 84% of sessions, compared to 61% for single-model applications — a 38% improvement. Task abandonment in single-model applications was most commonly triggered by output quality failures — responses that did not answer the user's question adequately, contained visible errors, or required so much correction that users abandoned the AI-assisted workflow entirely. Multi-model routing's ability to match task complexity to model capability reduced this failure pattern significantly.

Output acceptance rate: Users accepted AI-generated outputs without modification in 71% of interactions on multi-model platforms, versus 41% on single-model platforms — a 73% improvement. Output rejection — defined as users discarding AI output entirely and completing the task manually — occurred in 22% of single-model interactions versus 8% of multi-model interactions. Output rejection is the most direct measure of perceived AI output quality because it represents the user's explicit judgment that the AI output is less useful than no AI output.

Response quality rating: Users rating AI output quality on a five-point scale gave multi-model applications a median rating of 4.1, versus 2.9 for single-model applications. The 1.2-point quality gap persisted across all session types — first interactions, repeat users, and power users — indicating that the quality advantage of multi-model architecture is not attributable to novelty effects or specific user segments.

Why Multi-Model Architecture Produces Better User Experiences

The research identifies four mechanisms through which multi-model API architecture translates into measurably superior end-user experience outcomes.

Task-appropriate model capability matching is the primary driver, cited as the mechanism responsible for the largest share of the satisfaction differential in the research team's attribution analysis. Single-model deployments apply the same model to every user interaction regardless of complexity — a model strong enough for the most complex queries in the application's range may be poorly suited for simpler queries that represent the majority of user interactions, producing verbose, over-engineered responses to simple questions that users find unhelpful or confusing.

Multi-model routing matches each query to the model best suited for its specific requirements. A simple factual question routes to a fast, concise model. A complex multi-step reasoning request routes to a frontier reasoning model. A query involving image analysis routes to a multimodal specialist. Users receive responses calibrated to their actual query rather than responses calibrated to the worst-case complexity in the application's range. This calibration produces the output quality and tone that users consistently rate most highly — neither under-powered nor unnecessarily elaborate.

Response latency reduction is the second mechanism. Single-model deployments that route all traffic through frontier models — the common pattern for applications where the developer chose the best available model and applied it universally — incur frontier model latency on every interaction, including the 55–70% of interactions where a faster mid-tier or cost-efficient model would produce equivalent output. Median response latency for single-model frontier deployments in the study was 4.2 seconds. Multi-model deployments routing the majority of traffic to faster models achieved median latency of 1.8 seconds — a 57% reduction.

User satisfaction research in enterprise software consistently shows that response time is among the top three determinants of perceived quality for interactive AI applications. The 2.4-second latency advantage of multi-model deployments contributes directly to the satisfaction differential — users experience the application as faster, more responsive, and more capable, even in interactions where the output content is equivalent between the two architectures.

Hallucination and error rate reduction through multi-model cross-verification — consistent with AI.cc's separately published hallucination study finding a 61% error reduction with verification architecture — is the third mechanism. Users who receive AI outputs containing factual errors or logical inconsistencies rate their experience significantly lower than users who receive accurate outputs, even when other dimensions of the interaction are positive. The error reduction achievable through multi-model verification architectures directly improves the satisfaction scores of the users who would otherwise have received incorrect outputs.

Availability and consistency is the fourth mechanism. Single-model deployments that encounter provider rate limits during peak usage periods deliver degraded response times or errors to users caught in the rate limit queue. Multi-model deployments that distribute load across providers maintain consistent response quality and latency during peak periods that would saturate a single-provider deployment. Users experiencing consistent application performance rate their overall satisfaction higher than users experiencing performance variability — even when average performance across the full session is equivalent.

Industry Breakdown: Where the Satisfaction Gap Is Largest

The research documents significant variation in the size of the satisfaction differential across the 19 industries studied, with the gap largest in sectors where AI output accuracy directly affects user outcomes and smallest in sectors where AI assistance is primarily productivity-oriented.

Customer experience and support showed the largest absolute satisfaction gap, with multi-model deployments achieving NPS of 52 versus 17 for single-model — a 35-point difference. Customer support users have low tolerance for AI outputs that fail to resolve their issue, and high sensitivity to response latency. Multi-model routing's ability to deliver fast, accurate responses for routine queries while escalating complex issues to frontier models aligned precisely with the support use case's quality requirements.

E-commerce and retail showed a 31-point NPS gap (multi-model: 48, single-model: 17), driven primarily by the product recommendation and search personalization use cases where multi-model architectures routing to specialist recommendation models consistently outperformed general-purpose frontier models on user engagement metrics.

Healthcare administration showed a 29-point gap (multi-model: 44, single-model: 15), with the accuracy requirements of clinical documentation and patient communication driving strong user preference for multi-model verification architectures over single-model deployments.

Internal productivity tools showed the smallest gap at 18 points (multi-model: 41, single-model: 23), reflecting the higher tolerance of enterprise power users for AI output variability and their greater willingness to edit and correct AI outputs compared to external customer-facing users.

From Satisfaction Data to Business Outcomes

The research extends beyond satisfaction metrics to document the downstream business outcomes associated with the satisfaction differential, providing enterprise technology and product leaders with ROI context for multi-model infrastructure investment decisions.

Enterprises with AI application NPS above 40 — the threshold achieved by multi-model deployments in the study — reported AI feature adoption rates 2.8x higher than enterprises with NPS below 30, the range in which single-model deployments concentrated. Higher adoption rates translate directly into higher realized value from AI infrastructure investment — an application that users actively engage with generates business value; one that users abandon after poor initial experiences generates sunk cost.

Customer retention analysis across the e-commerce and financial services deployments in the study found that customers who interacted with multi-model AI applications showed 18% higher retention rates than customers who interacted with single-model applications, after controlling for other retention drivers. At enterprise customer lifetime values, an 18% retention improvement represents a return on multi-model infrastructure investment that dwarfs the incremental infrastructure cost.

The complete research methodology, industry-level data, satisfaction metric definitions, and business outcome analysis are available at docs.ai.cc/satisfaction-research.

About AI.cc

AI.cc is a unified AI API aggregation platform headquartered in Singapore, providing developers and enterprises with access to 312 AI models — including GPT-5.5, Claude Opus 4.7, Gemini 3.1 Pro, DeepSeek V4, Llama 4, Qwen 3.6-Plus, and more — through a single OpenAI-compatible API. Additional offerings include the OpenClaw AI agent framework, enterprise SLA plans, AI Translator API, and AI Web Scraping API.

Media Contact
Company Name: AICC
Email:Send Email
Country: United States
Website: https://www.ai.cc

Idiopathic Pulmonary Fibrosis Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Boehringer Ingelheim, PureTech, Guangzhou JOYO Pharma

Idiopathic Pulmonary Fibrosis Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Boehringer Ingelheim, PureTech, Guangzhou JOYO Pharma
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Idiopathic Pulmonary Fibrosis pipeline constitutes 70+ key companies continuously working towards developing 75+ Idiopathic Pulmonary Fibrosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

 

Idiopathic Pulmonary Fibrosis Pipeline Insight, 2026" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Idiopathic Pulmonary Fibrosis Market.

 

The Idiopathic Pulmonary Fibrosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Idiopathic Pulmonary Fibrosis Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Idiopathic Pulmonary Fibrosis treatment therapies with a considerable amount of success over the years.

  • Idiopathic Pulmonary Fibrosis companies working in the treatment market are Boehringer Ingelheim, PureTech, Guangzhou JOYO Pharma, Tvardi Therapeutics, Pliant Therapeutics, Inc., GlaxoSmithKline, Amgen, Bristol-Myers Squibb, Endeavor Biomedicines, Syndax Pharmaceuticals, Regend Therapeutics, and others, are developing therapies for the Idiopathic Pulmonary Fibrosis treatment

  • Emerging Idiopathic Pulmonary Fibrosis therapies in the different phases of clinical trials are- BI 1015550, OFEV (Nintedanib), Pirfenidone, SC1011, TTI-101, PLN-74809, GSK3915393, HZN-825, BMS-986278, taladegib, BI 181947, Axatilimab, REGEND001, and others are expected to have a significant impact on the Idiopathic Pulmonary Fibrosis market in the coming years.

  • In June 2026, The idiopathic pulmonary fibrosis (IPF) pipeline remained robust, with ongoing clinical development of investigational therapies including ENV-101, AZD8965, LTI-03, and other next-generation anti-fibrotic candidates designed to slow disease progression and preserve lung function.

  • In March 2026, PureTech Health reported positive Phase IIb ELEVATE-IPF trial results, demonstrating that deupirfenidone slowed the decline in lung function compared with the currently approved therapy pirfenidone, supporting its potential as a differentiated treatment option for idiopathic pulmonary fibrosis (IPF).

  • In January 2026, The idiopathic pulmonary fibrosis (IPF) clinical pipeline continued to advance, with ongoing Phase I–III clinical trials assessing novel anti-fibrotic therapies, including ENV-101, AZD8965, and other investigational candidates aimed at improving disease management.

  • In January 2026, Jascayd® (nerandomilast/BI 1015550) is a phosphodiesterase 4 (PDE4) inhibitor developed by Boehringer Ingelheim for the treatment of adults with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). It is the first and only preferential phosphodiesterase 4B (PDE4B) inhibitor approved for the treatment of IPF in adults. The therapy is available as 9 mg light yellow and 18 mg light red, oval, biconvex, film-coated tablets.

  • In October 2025, The U.S. Food and Drug Administration (FDA) has approved Jascayd® (nerandomilast) tablets for the treatment of idiopathic pulmonary fibrosis (IPF), marking the first new therapy authorized for IPF in over a decade.

  • In September 2025, PureTech Health plc (Nasdaq: PRTC, LSE: PRTC), a biotherapeutics company focused on advancing innovative science into impactful treatments, shared new data from the open-label extension (OLE) of its Phase 2b ELEVATE IPF trial evaluating deupirfenidone (LYT-100) in idiopathic pulmonary fibrosis (IPF). Results revealed that participants who had previously received placebo or pirfenidone for 26 weeks in the randomized phase and then transitioned to deupirfenidone for another 26 weeks in the OLE showed stabilized lung function. Presented as a late-breaking oral session at the 2025 European Respiratory Society (ERS) Congress in Amsterdam, these outcomes underscore deupirfenidone’s potential as a future standard of care in IPF treatment.

  • In September 2025, United Therapeutics is seeking approval for Tyvaso (treprostinil) in idiopathic pulmonary fibrosis (IPF) following positive results from a Phase III trial. In the TETON-2 study (NCT05255991), the inhaled prostacyclin mimetic significantly improved forced vital capacity (FVC), showing a 95.6 mL increase from baseline. Since FVC is a crucial indicator of breathing restriction in IPF, this outcome is notable. Additionally, the systemic vasodilator delayed the time to the first clinical worsening event, achieving its key secondary endpoint.

  • In May 2025, Endeavor BioMedicines, a clinical-stage biotech company developing treatments for serious conditions, presented a post hoc analysis from its completed Phase 2a trial of the investigational drug ENV-101 (taladegib). The findings indicated that patients with idiopathic pulmonary fibrosis (IPF) treated with ENV-101 for 12 weeks showed a marked reduction in pulmonary vessel volume, a significant increase in lung volume, and a trend toward decreased lung fibrosis compared to placebo. This analysis, utilizing Qureight’s advanced deep learning CT technology, was highlighted in a poster presentation at the ATS 2025 International Conference.

  • In February 2025, Pliant Therapeutics, Inc. (Nasdaq: PLRX) has temporarily halted enrollment and dosing in the ongoing BEACON-IPF Phase 2b trial of bexotegrast for idiopathic pulmonary fibrosis (IPF) following a prespecified data review and recommendations from the independent Data Safety Monitoring Board (DSMB). However, patients already enrolled will continue participation in the trial.

  • In January 2025, Mediar Therapeutics entered into a global licensing agreement with Eli Lilly and Company to progress MTX-463 into a Phase II clinical trial for idiopathic pulmonary fibrosis (IPF). MTX-463 is a novel human IgG1 antibody designed to inhibit WISP1-driven fibrotic signaling associated with multiple severe diseases.

 

Idiopathic Pulmonary Fibrosis Overview

Idiopathic Pulmonary Fibrosis (IPF) is a rare, chronic, and progressive lung disease where scar tissue (fibrosis) builds up in the lungs without a known cause. This scarring makes the lungs stiff, reducing their ability to deliver oxygen to the bloodstream. Symptoms include shortness of breath, dry cough, fatigue, and reduced exercise capacity. Over time, IPF worsens and can lead to respiratory failure.

 

Get a Free Sample PDF Report to know more about Idiopathic Pulmonary Fibrosis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/idiopathic-pulmonary-fibrosis-pipeline-insight

 

Emerging Idiopathic Pulmonary Fibrosis Drugs Under Different Phases of Clinical Development Include:

  • BI 1015550: Boehringer Ingelheim

  • OFEV (Nintedanib): Boehringer Ingelheim Pharma GmbH

  • Pirfenidone: PureTech

  • SC1011: Guangzhou JOYO Pharma

  • TTI-101: Tvardi Therapeutics

  • PLN-74809: Pliant Therapeutics, Inc.

  • GSK3915393: GlaxoSmithKline

  • HZN-825: Amgen

  • BMS-986278: Bristol-Myers Squibb

  • taladegib: Endeavor Biomedicines

  • BI 1819479: Boehringer Ingelheim

  • Axatilimab: Syndax Pharmaceuticals

  • REGEND001: Regend Therapeutics

 

Idiopathic Pulmonary Fibrosis Route of Administration

Idiopathic Pulmonary Fibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

  • Oral

  • Parenteral

  • Intravenous

  • Subcutaneous

  • Topical

 

Idiopathic Pulmonary Fibrosis Molecule Type Idiopathic Pulmonary Fibrosis Products have been categorized under various Molecule types, such as

  • Monoclonal

  • Antibody Peptides

  • Polymer

  • Small molecule

  • Gene therapy

 

Idiopathic Pulmonary Fibrosis Pipeline Therapeutics Assessment

  • Idiopathic Pulmonary Fibrosis Assessment by Product Type

  • Idiopathic Pulmonary Fibrosis By Stage and Product Type

  • Idiopathic Pulmonary Fibrosis Assessment by Route of Administration

  • Idiopathic Pulmonary Fibrosis By Stage and Route of Administration

  • Idiopathic Pulmonary Fibrosis Assessment by Molecule Type

  • Idiopathic Pulmonary Fibrosis by Stage and Molecule Type

 

DelveInsight's Idiopathic Pulmonary Fibrosis Report covers around 75+ products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I)

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

 

Further Idiopathic Pulmonary Fibrosis product details are provided in the report. Download the Idiopathic Pulmonary Fibrosis pipeline report to learn more about the emerging Idiopathic Pulmonary Fibrosis therapies

 

Some of the key companies in the Idiopathic Pulmonary Fibrosis Therapeutics Market include:

Key companies developing therapies for Idiopathic Pulmonary Fibrosis are - United Therapeutics, Bellerophon Therapeutics, and MediciNova, and others.

 

Idiopathic Pulmonary Fibrosis Pipeline Analysis:

The Idiopathic Pulmonary Fibrosis pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Idiopathic Pulmonary Fibrosis with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Idiopathic Pulmonary Fibrosis Treatment.

  • Idiopathic Pulmonary Fibrosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Idiopathic Pulmonary Fibrosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Idiopathic Pulmonary Fibrosis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Idiopathic Pulmonary Fibrosis drugs and therapies

 

Idiopathic Pulmonary Fibrosis Pipeline Market Drivers

  • Rising prevalence of IPF worldwide, particularly in aging

  • populations, driving demand for new therapies.

  • Advancements in diagnostics leading to earlier and more accurate disease detection.

  • Strong research and development investments by pharmaceutical companies targeting novel antifibrotic and immunomodulatory mechanisms.

  • Regulatory support for orphan drugs, accelerating approvals and incentivizing innovation

 

Idiopathic Pulmonary Fibrosis Pipeline Market Barriers

  • Unclear disease etiology and complex pathophysiology make drug development challenging

  • High failure rate in clinical trials due to limited efficacy or safety issues

  • Expensive development costs for orphan disease therapies, affecting smaller biotech players

  • Limited patient population makes recruitment for large-scale trials difficult

  • Side effects of existing antifibrotic drugs hinder patient adherence

  • Regulatory challenges in proving long-term efficacy and safety of emerging therapies

 

Scope of Idiopathic Pulmonary Fibrosis Pipeline Drug Insight

  • Coverage: Global

  • Key Idiopathic Pulmonary Fibrosis Companies: Boehringer Ingelheim, PureTech, Guangzhou JOYO Pharma, Tvardi Therapeutics, Pliant Therapeutics, Inc., GlaxoSmithKline, Amgen, Bristol-Myers Squibb, Endeavor Biomedicines, Syndax Pharmaceuticals, Regend Therapeutics, and others

  • Key Idiopathic Pulmonary Fibrosis Therapies: BI 1015550, OFEV (Nintedanib), Pirfenidone, SC1011, TTI-101, PLN-74809, GSK3915393, HZN-825, BMS-986278, taladegib, BI 181947, Axatilimab, REGEND001, and others

  • Idiopathic Pulmonary Fibrosis Therapeutic Assessment: Idiopathic Pulmonary Fibrosis current marketed and Idiopathic Pulmonary Fibrosis emerging therapies

  • Idiopathic Pulmonary Fibrosis Market Dynamics: Idiopathic Pulmonary Fibrosis market drivers and Idiopathic Pulmonary Fibrosis market barriers

 

Request for Sample PDF Report for Idiopathic Pulmonary Fibrosis Pipeline Assessment and clinical trials

 

Table of Contents

1. Idiopathic Pulmonary Fibrosis Report Introduction

2. Idiopathic Pulmonary Fibrosis Executive Summary

3. Idiopathic Pulmonary Fibrosis Overview

4. Idiopathic Pulmonary Fibrosis- Analytical Perspective In-depth Commercial Assessment

5. Idiopathic Pulmonary Fibrosis Pipeline Therapeutics

6. Idiopathic Pulmonary Fibrosis Late Stage Products (Phase II/III)

7. Idiopathic Pulmonary Fibrosis Mid Stage Products (Phase II)

8. Idiopathic Pulmonary Fibrosis Early Stage Products (Phase I)

9. Idiopathic Pulmonary Fibrosis Preclinical Stage Products

10. Idiopathic Pulmonary Fibrosis Therapeutics Assessment

11. Idiopathic Pulmonary Fibrosis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Idiopathic Pulmonary Fibrosis Key Companies

14. Idiopathic Pulmonary Fibrosis Key Products

15. Idiopathic Pulmonary Fibrosis Unmet Needs

16 . Idiopathic Pulmonary Fibrosis Market Drivers and Barriers

17. Idiopathic Pulmonary Fibrosis Future Perspectives and Conclusion

18. Idiopathic Pulmonary Fibrosis Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on

life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Mesothelioma Pipeline 2026: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | GSK, Merck, Bristol-Myers Squibb, AstraZeneca, Roche, Novartis, Pfizer Inc

Mesothelioma Pipeline 2026: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | GSK, Merck, Bristol-Myers Squibb, AstraZeneca, Roche, Novartis, Pfizer Inc
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Mesothelioma pipeline constitutes 45+ key companies continuously working towards developing 50+ Mesothelioma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

 

Mesothelioma Pipeline Insight, 2026" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Mesothelioma Market.

 

The Mesothelioma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Mesothelioma Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Mesothelioma treatment therapies with a considerable amount of success over the years.

  • Mesothelioma companies working in the treatment market are The Netherlands Cancer Institute, Bristol-Myers Squibb, PrECOG, LLC., Memorial Sloan Kettering Cancer Center, ETOP IBCSG Partners Foundation, MedImmune LLC, Ã…slaug Helland, AstraZeneca, Oncotelic Inc., Hyogo Medical University, Trizell Ltd, RS Oncology LLC, Vivace Therapeutics, Inc, TCR2 Therapeutics, Sanofi, ImmVira Pharma Co. Ltd, TCR2 Therapeutics, CRISPR Therapeutics, Biotheus Inc., and others, are developing therapies for the Mesothelioma treatment

  • Emerging Mesothelioma therapies in the different phases of clinical trials are- Pembrolizumab, Nivolumab, Durvalumab, Sacituzumab govitecan-hziy, Carboplatin, Tremelimumab, ipilimumab, Volrustomig, OT-101, Lenvatinib, rAd-IFN, RSO-021, VT3989, gavo-cel, THOR-707, T3011, TC-510, CTX131, PM8002, and others are expected to have a significant impact on the Mesothelioma market in the coming years.

  • In May 2026, Researchers continued enrolling patients in clinical trials evaluating mesothelin-targeted CAR-T cell therapies, bispecific antibodies, and personalized immunotherapy strategies aimed at enhancing treatment outcomes for individuals with advanced mesothelioma.

  • In April 2026, The ATOMIC-Meso trial assessed the efficacy of weekly intramuscular pegargiminase in combination with pemetrexed and platinum-based chemotherapy compared with placebo plus chemotherapy in previously untreated patients with mesothelioma. The study represents one of the most advanced late-stage clinical development programs for the disease.

  • In January 2026, Multiple Phase I–III clinical trials investigating immunotherapies, targeted therapies, CAR-T cell therapies, and tumor-targeted agents continued to enroll patients with malignant pleural mesothelioma, reflecting sustained progress in the disease's therapeutic pipeline.

  • In August 2025, VT3989, a TEAD autopalmitoylation inhibitor, has been granted orphan drug designation by the FDA for treating adult mesothelioma patients, as announced by Vivace Therapeutics.

  • In July 2025, The U.S. FDA has awarded orphan drug designation to VT3989 for mesothelioma treatment in the United States, according to Vivace Therapeutics. VT3989 is an investigational therapy that inhibits palmitoylation in TEAD proteins, key components of the Hippo pathway, which regulates cell growth and division.

  • In April 2025, GSK’s Zejula (niraparib) demonstrated a 27% reduction in the risk of disease progression or death in mesothelioma patients in an investigator-initiated Phase II trial. The NERO study (NCT05455424) evaluated Zejula’s effectiveness in 88 mesothelioma patients who experienced relapse following prior platinum-based systemic therapy. The trial is sponsored by the University Hospital Southampton NHS Foundation Trust and funded by Asthma + Lung UK, with additional support from Mesothelioma UK and the Mavis Nye Foundation.

  • In January 2025, Insilico Medicine ("Insilico"), a clinical-stage AI-driven biotechnology company, has announced that the first patient has been dosed in its global multicenter Phase I trial of ISM6331, a novel pan-TEAD inhibitor developed using its AI-powered generative chemistry platform, Chemistry42. ISM6331 is being investigated for the treatment of mesothelioma and other solid tumors. Notably, it is Insilico’s leading oncology program within its AI-driven drug discovery pipeline and has received Orphan Drug Designation (ODD) from the FDA for mesothelioma treatment.

 

Mesothelioma Overview

Mesothelioma is a type of cancer that develops from the thin layer of tissue that covers many of the internal organs (mesothelium). The most common form is pleural mesothelioma, which affects the lining of the lungs and is often associated with exposure to asbestos fibers. Other less common forms include peritoneal mesothelioma (affecting the lining of the abdomen), and pericardial mesothelioma (affecting the lining around the heart).

 

Get a Free Sample PDF Report to know more about Mesothelioma Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/mesothelioma-pipeline-insight

 

Emerging Mesothelioma Drugs Under Different Phases of Clinical Development Include:

  • Pembrolizumab: The Netherlands Cancer Institute

  • Nivolumab: Bristol-Myers Squibb

  • Durvalumab: PrECOG, LLC.

  • Sacituzumab govitecan-hziy: Memorial Sloan Kettering Cancer Center

  • Carboplatin: ETOP IBCSG Partners Foundation

  • Tremelimumab: MedImmune LLC

  • ipilimumab: Ã…slaug Helland

  • Volrustomig: AstraZeneca

  • OT-101: Oncotelic Inc.

  • Lenvatinib: Hyogo Medical University

  • rAd-IFN: Trizell Ltd

  • RSO-021: RS Oncology LLC

  • VT3989: Vivace Therapeutics, Inc

  • gavo-cel: TCR2 Therapeutics

  • THOR-707: Sanofi

  • T3011: ImmVira Pharma Co. Ltd

  • TC-510: TCR2 Therapeutics

  • CTX131: CRISPR Therapeutics

  • PM8002: Biotheus Inc.

 

Mesothelioma Route of Administration

Mesothelioma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

  • Oral

  • Parenteral

  • Intravenous

  • Subcutaneous

  • Topical

 

Mesothelioma Molecule Type

Mesothelioma Products have been categorized under various Molecule types, such as

  • Recombinant fusion proteins

  • Small molecule

  • Monoclonal antibody

  • Peptide

  • Polymer

  • Gene therapy

 

Mesothelioma Pipeline Therapeutics Assessment

  • Mesothelioma Assessment by Product Type

  • Mesothelioma By Stage and Product Type

  • Mesothelioma Assessment by Route of Administration

  • Mesothelioma By Stage and Route of Administration

  • Mesothelioma Assessment by Molecule Type

  • Mesothelioma by Stage and Molecule Type

 

DelveInsight's Mesothelioma Report covers around 50+ products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I)

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

 

Further Mesothelioma product details are provided in the report. Download the Mesothelioma pipeline report to learn more about the emerging Mesothelioma therapies

 

Some of the key companies in the Mesothelioma Therapeutics Market include:

Key companies developing therapies for Mesothelioma are - Merck & Co., Inc., Bristol-Myers Squibb, AstraZeneca, Roche, Novartis, Pfizer Inc., Eli Lilly and Company, Johnson & Johnson, GlaxoSmithKline plc (GSK), AbbVie Inc., Sanofi, and others.

 

Mesothelioma Pipeline Analysis:

  • The Mesothelioma pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Mesothelioma with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Mesothelioma Treatment.

  • Mesothelioma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Mesothelioma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Mesothelioma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Mesothelioma drugs and therapies

 

Mesothelioma Pipeline Market Drivers

  • Rising incidence of malignant pleural mesothelioma due to historical asbestos exposure worldwide.

  • Increasing focus on immunotherapy, including immune checkpoint inhibitors, CAR-T cell therapies, and mesothelin-targeted treatments.

  • Strong pipeline of targeted therapies, gene therapies, and personalized medicine approaches aimed at improving patient outcomes.

  • Growing number of clinical trials supported by regulatory incentives such as Orphan Drug, Fast Track, and Breakthrough Therapy designations.

 

Mesothelioma Pipeline Market Barriers

  • Low disease prevalence limits patient recruitment and slows clinical trial enrollment.

  • Late-stage diagnosis and aggressive disease progression reduce the treatment window and clinical trial participation.

  • High development costs and lengthy clinical timelines for rare oncology therapies.

  • Limited understanding of mesothelioma biology and tumor heterogeneity complicates drug development.

  • Difficulty demonstrating significant survival benefits in clinical studies due to small patient populations.

 

Scope of Mesothelioma Pipeline Drug Insight

  • Coverage: Global

  • Key Mesothelioma Companies: The Netherlands Cancer Institute, Bristol-Myers Squibb, PrECOG, LLC., Memorial Sloan Kettering Cancer Center, ETOP IBCSG Partners Foundation, MedImmune LLC, Ã…slaug Helland, AstraZeneca, Oncotelic Inc., Hyogo Medical University, Trizell Ltd, RS Oncology LLC, Vivace Therapeutics, Inc, TCR2 Therapeutics, Sanofi, ImmVira Pharma Co. Ltd, TCR2 Therapeutics, CRISPR Therapeutics, Biotheus Inc., and others

  • Key Mesothelioma Therapies: Pembrolizumab, Nivolumab, Durvalumab, Sacituzumab govitecan-hziy, Carboplatin, Tremelimumab, ipilimumab, Volrustomig, OT-101, Lenvatinib, rAd-IFN, RSO-021, VT3989, gavo-cel, THOR-707, T3011, TC-510, CTX131, PM8002, and others

  • Mesothelioma Therapeutic Assessment: Mesothelioma current marketed and Mesothelioma emerging therapies

  • Mesothelioma Market Dynamics: Mesothelioma market drivers and Mesothelioma market barriers

 

Request for Sample PDF Report for Mesothelioma Pipeline Assessment and clinical trials

 

Table of Contents

1. Mesothelioma Report Introduction

2. Mesothelioma Executive Summary

3. Mesothelioma Overview

4. Mesothelioma- Analytical Perspective In-depth Commercial Assessment

5. Mesothelioma Pipeline Therapeutics

6. Mesothelioma Late Stage Products (Phase II/III)

7. Mesothelioma Mid Stage Products (Phase II)

8. Mesothelioma Early Stage Products (Phase I)

9. Mesothelioma Preclinical Stage Products

10. Mesothelioma Therapeutics Assessment

11. Mesothelioma Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Mesothelioma Key Companies

14. Mesothelioma Key Products

15. Mesothelioma Unmet Needs

16 . Mesothelioma Market Drivers and Barriers

17. Mesothelioma Future Perspectives and Conclusion

18. Mesothelioma Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679 Source: https://www.delveinsight.com/report-store.php
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Top Asset Managers in Singapore (2026) Report Published by Metaclade Research

Metaclade Research Publishes Its Latest Research Report Recognizing the Top Asset Managers in Singapore (2026)

Metaclade Research has published its latest market research report, "Top Asset Managers in Singapore," offering an in-depth examination of the asset managers shaping the city-state's position as Asia's asset management capital.

The report evaluates leading asset managers based on investment performance, platform breadth and capability, pan-Asian reach, institutional quality, client alignment and franchise strength, and innovation and adaptability across Singapore. After reviewing some of the region's most influential managers, Metaclade Research ranked Granite Asia as the strongest overall asset manager ovperating from Singapore.

Singapore has become the undisputed asset management capital of Asia and one of the most important investment centers in the world. Managers across traditional equities and fixed income, multi-asset, alternatives, and private capital continue attracting significant attention as Asian wealth creation, the family office boom, and the structural migration toward private markets accelerate throughout the region.

According to the report, Granite Asia earned the number one position due to its multi-strategy private capital platform spanning growth equity, buyouts, and private credit, its founder-aligned partnership model, extensive regional connectivity, and the deepest entrepreneur network of any manager anchored in the city-state.

"Granite Asia has become the top asset manager in Singapore by building out a genuine multi-strategy platform spanning growth equity, buyouts, and private credit, paired with the deepest entrepreneur network of any private capital manager in the region," the report states. "Its founder-aligned partnership model, research-led sector expertise, and hands-on approach to value creation place it firmly at the top."

In addition to Granite Asia, the report highlights several other prominent managers that continue to anchor Singapore's asset management ecosystem, including Fullerton Fund Management, Lion Global Investors, Eastspring Investments, Nikko Asset Management Asia, UOB Asset Management, Avanda Investment Management, APS Asset Management, Dymon Asia Capital, and Amundi (Singapore).

The report identifies several key trends currently influencing Singapore's asset management sector:

  • Rapid growth of Asian wealth seeking professional management
  • Expansion of the family office and private capital ecosystem
  • Singapore's deepening role as the neutral hub for pan-Asian capital flows
  • Increasing global institutional allocations to Asia routed through Singapore
  • The structural shift from traditional long-only management toward private markets and alternatives
  • Growing emphasis on genuine regional expertise and institutional-quality operations


Researchers note that Singapore's asset management landscape continues to mature, supported by a world-class regulatory framework, political stability and rule of law, favorable fund structuring options such as the Variable Capital Company framework, and a deep professional services ecosystem.

Markets across Southeast Asia, India, Greater China, and North Asia remain important centers for investment activity, producing opportunities that are attracting attention from both regional and global investors routed through Singapore.

The report concludes that asset managers will continue playing a central role in cementing Singapore's position as Asia's asset management capital, with the managers that most powerfully shape the next decade being those that combine genuine regional expertise with institutional-quality operations across both public and private markets.

The full report, "Top Asset Managers in Singapore," is now available at https://metaclade.com/top-asset-managers-in-singapore-2026

Media Contact
Company Name: Metaclade Research
Contact Person: Allison Brown
Email:Send Email
Country: United States
Website: metaclade.com

Scleroderma Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Bayer, Novartis, GSK, Boehringer Ingelheim, Celgene Corp., Johnson & Johnson

Scleroderma Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Bayer, Novartis, GSK, Boehringer Ingelheim, Celgene Corp., Johnson & Johnson
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Scleroderma pipeline constitutes 45+ key companies continuously working towards developing 50+ Scleroderma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

 

Scleroderma Pipeline Insight, 2026" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Scleroderma Market.

 

The Scleroderma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Scleroderma Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Scleroderma treatment therapies with a considerable amount of success over the years.

  • Scleroderma companies working in the treatment market are Genentech, AnaMar AB, Acceleron Pharma, Boehringer Ingelheim, Vedotin Seagen, Horizon Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, and others, are developing therapies for the Scleroderma treatment

  • Emerging Scleroderma therapies in the different phases of clinical trials are- RO7303509, AM 1476, MK-2225, BI 685509, Brentuximab, HZN-825, MT-0551, and others are expected to have a significant impact on the Scleroderma market in the coming years.

  • In April 2026, Several global clinical trials continued to enroll patients for the evaluation of novel biologics, cytokine inhibitors, and precision medicine-based therapies in the treatment of diffuse cutaneous systemic sclerosis (dcSSc) and systemic sclerosis-associated interstitial lung disease (SSc-ILD).

  • In January 2026, Ongoing Phase III clinical trials investigating BENLYSTA (belimumab) for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD) continued patient follow-up, with topline results expected after 2026.

 

Scleroderma Overview

Scleroderma is a chronic autoimmune disease that causes the hardening and thickening of the skin and connective tissues. It can also affect internal organs, blood vessels, and the immune system, leading to complications ranging from skin changes to organ dysfunction.

 

Get a Free Sample PDF Report to know more about Scleroderma Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/scleroderma-pipeline-insight

 

Emerging Scleroderma Drugs Under Different Phases of Clinical Development Include:

  • RO7303509: Genentech

  • AM 1476: AnaMar AB

  • MK-2225: Acceleron Pharma

  • BI 685509: Boehringer Ingelheim

  • Brentuximab: Vedotin Seagen

  • HZN-825: Horizon Pharmaceuticals

  • MT-0551: Mitsubishi Tanabe Pharma Corporation

 

Scleroderma Route of Administration

Scleroderma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

  • Oral

  • Parenteral

  • Intravenous

  • Subcutaneous

  • Topical

 

Scleroderma Molecule Type

Scleroderma Products have been categorized under various Molecule types, such as

  • Recombinant fusion proteins

  • Small molecule

  • Monoclonal antibody

  • Peptide

  • Polymer

  • Gene therapy

 

Scleroderma Pipeline Therapeutics Assessment

  • Scleroderma Assessment by Product Type

  • Scleroderma By Stage and Product Type

  • Scleroderma Assessment by Route of Administration

  • Scleroderma By Stage and Route of Administration

  • Scleroderma Assessment by Molecule Type

  • Scleroderma by Stage and Molecule Type

 

DelveInsight's Scleroderma Report covers around 50+ products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I)

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

 

Further Scleroderma product details are provided in the report. Download the Scleroderma pipeline report to learn more about the emerging Scleroderma therapies

 

Some of the key companies in the Scleroderma Therapeutics Market include:

Key companies developing therapies for Scleroderma are - Boehringer Ingelheim International GmbH, Celgene Corporation, Johnson & Johnson Services, Inc., Prometic Life Sciences Inc., Kadmon Holdings Inc., Emerald Health Pharmaceuticals, Cytori Therapeutics Inc., Bayer AG, F. Hoffman La Roche Ltd, arGentis Pharmaceuticals LLC, GlaxoSmithKline PLC (GSK), Novartis AG, and others.

 

Scleroderma Pipeline Analysis:

The Scleroderma pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Scleroderma with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Scleroderma Treatment.

  • Scleroderma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Scleroderma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Scleroderma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Scleroderma drugs and therapies

 

Scleroderma Pipeline Market Drivers

  • Pharmaceutical and Biotechnology Industries striving on the development of new therapy, increased Awareness among people related to the disease are some of the important factors that are fueling the Scleroderma Market.

 

Scleroderma Pipeline Market Barriers

  • However, higher healthcare cost, adverse effects associated with the drugs and other factors are creating obstacles in the Scleroderma Market growth.

 

Scope of Scleroderma Pipeline Drug Insight

  • Coverage: Global

  • Key Scleroderma Companies: Genentech, AnaMar AB, Acceleron Pharma, Boehringer Ingelheim, Vedotin Seagen, Horizon Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, and others

  • Key Scleroderma Therapies: RO7303509, AM 1476, MK-2225, BI 685509, Brentuximab, HZN-825, MT-0551, and others

  • Scleroderma Therapeutic Assessment: Scleroderma current marketed and Scleroderma emerging therapies

  • Scleroderma Market Dynamics: Scleroderma market drivers and Scleroderma market barriers

 

Request for Sample PDF Report for Scleroderma Pipeline Assessment and clinical trials

 

Table of Contents

1. Scleroderma Report Introduction

2. Scleroderma Executive Summary

3. Scleroderma Overview

4. Scleroderma- Analytical Perspective In-depth Commercial Assessment

5. Scleroderma Pipeline Therapeutics

6. Scleroderma Late Stage Products (Phase II/III)

7. Scleroderma Mid Stage Products (Phase II)

8. Scleroderma Early Stage Products (Phase I)

9. Scleroderma Preclinical Stage Products

10. Scleroderma Therapeutics Assessment

11. Scleroderma Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Scleroderma Key Companies

14. Scleroderma Key Products

15. Scleroderma Unmet Needs

16 . Scleroderma Market Drivers and Barriers

17. Scleroderma Future Perspectives and Conclusion

18. Scleroderma Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Spasticity Pipeline 2026: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Huons, Supernus Pharma, Sun Pharma, Acorda Therapeutics, Merz Pharmaceuticals GmbH

Spasticity Pipeline 2026: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Huons, Supernus Pharma, Sun Pharma, Acorda Therapeutics, Merz Pharmaceuticals GmbH
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Spasticity pipeline constitutes 10+ key companies continuously working towards developing 12+ Spasticity treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

 

Spasticity Pipeline Insight, 2026" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Spasticity Market.

 

The Spasticity Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Spasticity Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Spasticity treatment therapies with a considerable amount of success over the years.

  • Spasticity companies working in the treatment market are Lundbeck, Revance Therapeutics, Ipsen, Saol Therapeutics, Huons, Supernus Pharma, Sun Pharma, Acorda Therapeutics, Merz Pharmaceuticals GmbH, Medy-Tox, XenoPort, Inc., Medtronic Neuro, Daewoong Pharma, and others, are developing therapies for the Spasticity treatment

  • Emerging Spasticity therapies in the different phases of clinical trials are- Lu AG06466, DAXXIFY, IPN10200, SIL 1002, HU-014, MYOBLOC, SPARC1103, Tizanidine, CORETOX®, XP19986 SR1, intrathecal baclofen, Botulinum toxin type A, and others are expected to have a significant impact on the Spasticity market in the coming years.

  • In June 2026, Pipeline development continued to focus on enhancing treatment durability, precision drug delivery systems, neuromodulation technologies, and personalized rehabilitation approaches to improve long-term functional outcomes for individuals living with chronic spasticity.

  • In January 2026, Multiple Phase II and Phase III clinical trials continued to assess innovative intrathecal baclofen delivery systems, next-generation botulinum toxin formulations, and neuromodulation technologies for the treatment of spasticity associated with stroke, multiple sclerosis, spinal cord injury, and cerebral palsy.

  • In July 2025, A global Phase II clinical trial, BALANCE-MSS-1 (NCT06782490), has been launched to evaluate BMS-986368, an investigational oral therapy, for the treatment of spasticity associated with multiple sclerosis (MS), characterized by muscle stiffness and spasms. The study plans to enroll approximately 200 adults with MS who have experienced spasticity for at least six months. Recruitment is underway at sites across the United States, Australia, Canada, Puerto Rico, and several European countries. The trial is sponsored by Celgene and is being conducted by Bristol Myers Squibb, which acquired Celgene in 2019.

  • In April 2025, The US FDA has approved BlackfinBio’s IND application to initiate a Phase I/II trial of BFB-101, an adeno-associated virus gene therapy for hereditary spastic paraplegia type 47 (SPG47). The therapy has also received orphan drug and rare pediatric disease designations for SPG47, a rare disorder caused by AP4B1 gene mutations, leading to progressive lower-limb spasticity and developmental delays in children.

  • In March 2025, BlackfinBio Limited announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for its innovative adeno-associated virus (AAV) gene therapy designed to treat Hereditary Spastic Paraplegia Type 47 (SPG47).

 

Spasticity Overview

Spasticity is a condition characterized by an abnormal increase in muscle tone or stiffness, which can interfere with movement, speech, and gait. It is caused by damage to or a disruption in the pathways that control muscle movement, typically within the brain or spinal cord.

 

Get a Free Sample PDF Report to know more about Spasticity Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/spasticity-pipeline-insight

 

Emerging Spasticity Drugs Under Different Phases of Clinical Development Include:

  • Lu AG06466: Lundbeck

  • DAXXIFY: Revance Therapeutics

  • IPN10200: Ipsen

  • HU-014: Huons

  • SL-1002: Saol Therapeutics Inc

  • MYOBLOC: Supernus Pharma

  • SPARC1103: Sun Pharma

  • Tizanidine: Acorda Therapeutics

  • botulinum A toxin: Merz Pharmaceuticals GmbH

  • CORETOX®: Medy-Tox

  • XP19986 SR1: XenoPort, Inc.

  • intrathecal baclofen: MedtronicNeuro

 

Spasticity Route of Administration

Spasticity pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

  • Oral

  • Parenteral

  • Intravenous

  • Subcutaneous

  • Topical

 

Spasticity Molecule Type

Spasticity Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy

 

Spasticity Pipeline Therapeutics Assessment

  • Spasticity Assessment by Product Type

  • Spasticity By Stage and Product Type

  • Spasticity Assessment by Route of Administration

  • Spasticity By Stage and Route of Administration

  • Spasticity Assessment by Molecule Type

  • Spasticity by Stage and Molecule Type

 

DelveInsight's Spasticity Report covers around 12+ products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I)

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

 

Further Spasticity product details are provided in the report. Download the Spasticity pipeline report to learn more about the emerging Spasticity therapies

 

Spasticity Pipeline Analysis:

The Spasticity pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Spasticity with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Spasticity Treatment.

  • Spasticity key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Spasticity Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Spasticity market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Spasticity drugs and therapies

 

Spasticity Pipeline Market Drivers

  • Increasing prevalence of stroke, multiple sclerosis, and brain injury drive the market, increasing R&D for developing effective therapies are some of the important factors that are fueling the Spasticity Market.

 

Spasticity Pipeline Market Barriers

  • However, high cost of the treatment, lack of disease awareness in emerging economies and other factors are creating obstacles in the Spasticity Market growth.

 

Scope of Spasticity Pipeline Drug Insight

  • Coverage: Global

  • Key Spasticity Companies: Lundbeck, Revance Therapeutics, Ipsen, Saol Therapeutics, Huons, Supernus Pharma, Sun Pharma, Acorda Therapeutics, Merz Pharmaceuticals GmbH, Medy-Tox, XenoPort, Inc., Medtronic Neuro, Daewoong Pharma, and others

  • Key Spasticity Therapies: Lu AG06466, DAXXIFY, IPN10200, SIL 1002, HU-014, MYOBLOC, SPARC1103, Tizanidine, CORETOX®, XP19986 SR1, intrathecal baclofen, Botulinum toxin type A, and others

  • Spasticity Therapeutic Assessment: Spasticity current marketed and Spasticity emerging therapies

  • Spasticity Market Dynamics: Spasticity market drivers and Spasticity market barriers

 

Request for Sample PDF Report for Spasticity Pipeline Assessment and clinical trials

 

Table of Contents

1. Spasticity Report Introduction

2. Spasticity Executive Summary

3. Spasticity Overview

4. Spasticity- Analytical Perspective In-depth Commercial Assessment

5. Spasticity Pipeline Therapeutics

6. Spasticity Late Stage Products (Phase II/III)

7. Spasticity Mid Stage Products (Phase II)

8. Spasticity Early Stage Products (Phase I)

9. Spasticity Preclinical Stage Products

10. Spasticity Therapeutics Assessment

11. Spasticity Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Spasticity Key Companies

14. Spasticity Key Products

15. Spasticity Unmet Needs

16 . Spasticity Market Drivers and Barriers

17. Spasticity Future Perspectives and Conclusion

18. Spasticity Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/